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Abstract
Background: [
11C]Flumazenil and positron emission tomography (PET) are used clinically to assess gamma-
aminobutyric acid (GABA)-ergic function and to localize epileptic foci prior to resective surgery. Enhanced P-
glycoprotein (P-gp) activity has been reported in epilepsy and this may confound interpretation of clinical scans if
[
11C]flumazenil is a P-gp substrate. The purpose of this study was to investigate whether [
11C]flumazenil is a P-gp
substrate.
Methods: [
11C]Flumazenil PET scans were performed in wild type (WT) (n = 9) and Mdr1a/1b, (the genes that
encode for P-gp) double knockout (dKO) (n = 10) mice, and in naive rats (n = 10). In parallel to PET scanning, [
11C]
flumazenil plasma concentrations were measured in rats. For 6 of the WT and 6 of the dKO mice a second, [
11C]
flumazenil scan was acquired after administration of the P-gp inhibitor tariquidar. Cerebral [
11C]flumazenil
concentrations in WT and Mdr1a/1b dKO mice were compared (genetic disruption model). Furthermore, pre and
post P-gp-blocking cerebral [
11C]flumazenil concentrations were compared in all animals (pharmacological
inhibition model).
Results: Mdr1a/1b dKO mice had approximately 70% higher [
11C]flumazenil uptake in the brain than WT mice.
After administration of tariquidar, cerebral [
11C]flumazenil uptake in WT mice increased by about 80% in WT mice,
while it remained the same in Mdr1a/1b dKO mice. In rats, cerebral [
11C]flumazenil uptake increased by about 60%
after tariquidar administration. Tariquidar had only a small effect on plasma clearance of flumazenil.
Conclusions: The present study showed that [
11C]flumazenil is a P-gp substrate in rodents. Consequently, altered
cerebral [
11C]flumazenil uptake, as observed in epilepsy, may not reflect solely GABAA receptor density changes but
also changes in P-gp activity.
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Background
An important potential mechanism of pharmacoresis-
tance in people with epilepsy is inadequate access of
antiepileptic drugs to their intrabrain targets. This may
be caused by limited drug distribution across the blood-
brain barrier (BBB) due to increased activity of multi-
drug efflux transporters, such as P-glycoprotein (P-gp)
[1]. Recent ex vivo data suggest that the positron emis-
sion tomography (PET) radioligand [
11C]flumazenil
might be a P-gp substrate [2]. Currently, [
11C]flumazenil
is used clinically as a PET tracer for assessment of
gamma-aminobutyric acid (GABA)A receptor mediated
inhibition in epilepsy and to determine focus localiza-
tion prior to resective surgery [3,4]. If [
11C]flumazenil is
indeed a P-gp substrate, an anticipated increase in P-gp
function at the BBB due to epilepsy could lead to a
r e d u c t i o ni nb r a i nu p t a k eo f[
11C]flumazenil and
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GABA-ergic function.
Whereas in humans, the multidrug resistance 1
(MDR1)g e n ee n c o d e sf o rP - g pi nm i c ea n dr a t st w o
genes (Mdr1a and Mdr1b) encode for two subtypes of
P-gp that together perform the same function as human
P-gp [5]. To investigate the impact of P-gp on drug dis-
tribution, two approaches can be followed. The first is
t h eu s eo fg e n e t i c a l l yP - g p - d i s r u p t e dMdr1a/Mdr1b
mice (double knockout (dKO), Mdr1a/1b dKO) model
[6], the second is the pharmacological inhibition of P-
gp. A number of compounds have been used for phar-
macological inhibition. The third generation P-gp
blocker tariquidar is one of the most potent modulators
of P-gp [7,8]. It has been shown that P-gp inhibition fol-
lowing intravenous administration of tariquidar in rats
occurs fast and has long duration [9,10].
Potentially genetic disruption of the P-gp encoding
genes may induce upregulation of other transporters (i.
e., multidrug resistance protein 1, and breast cancer
resistant protein (Bcrp)1), while chemical inhibition of
P-gp function might also inhibit other transporters, such
as Bcrp1, in the case of tariquidar [11]. Therefore, in the
present study, a combination of both approaches was
used to investigate whether [
11C]flumazenil is indeed a
P-gp substrate in rodents, i.e., to assess whether changes
in cerebral [
11C]flumazenil uptake may reflect not only
changes in GABAA receptor density, but also in P-gp
activity. For that reason, [
11C]flumazenil scans, before
and after administration of the P-gp blocker tariquidar
(pharmacological inhibition model), were performed in
both Mdr1a/1b dKO and wild type (WT) mice (genetic
disruption model) and in rats.
Methods
Animals
Mdr1a/1b dKO (FVB.129P2-Abcb1a
tm1BorAbcb1b
tm1Bor
N12, male, n = 10) and WT (FVB/NTac, male, n = 10)
mice (Taconic, Ejby, Denmark), and adult Sprague-Dawley
rats (Harlan, Horst, The Netherlands, male, n = 11) were
used. Approval of the institutional animal ethics commit-
tee was obtained, and all experiments were carried out in
accordance with the Dutch Law on Animal Experimenta-
tion and guidelines of the institutional committee on ani-
mal experimentation. All animals were kept at a constant
temperature of 21°C and a 12-h light/dark cycle, in which
the lights were switched on at 8 a.m. Animals had unrest-
ricted access to food (Teklad Global Rodent Diet, Harlan,
Madison, WI, USA) and water. Studies were performed
after approximately 1 week of habituation.
Animal preparation and anesthesia
In each mouse a cannula was inserted in the jugular
vein and one in the intraperitoneal space 1-2 h prior to
PET scanning. Each rat underwent cannulation of the
femoral vein and artery 1-2 h before PET scanning.
From the start of surgery until the end of scanning, ani-
mals were anesthetized with a combination of (S)-keta-
mine and medetomidine (Domitor, Pfizer, Capelle a/d
IJssel, The Netherlands). Mice received an intraperito-
neal injection of 75 mg·kg
-1 (S)-ketamine (Ketanest S,
Pfizer BV, Capelle aan de IJssel, The Netherlands) and
1.0 mg·kg
-1 medetomidineMaintenance anesthesia was
administered via the intraperitoneal cannula (37.5
mg·kg
-1·h
-1 (S)-ketamine and 0.5 mg·kg
-1·h
-1 medetomi-
dine). Rats first received an intraperitoneal injection of
60 mg·kg
-1 ketamine (Ketalar, Parke-Davis, Hoofddorp,
The Netherlands) followed by a second intraperitoneal
injection of 0.4 mg·kg
-1 medetomidine. To maintain
anesthesia, an intravenous infusion into the tail vein of
10 mg·kg
-1·h
-1 ketamine and 0.1 mg·kg
-1·h
-1 medetomi-
dine was administered. This was started between 60 and
120 min after the first intraperitoneal injections and, in
most animals, the infusion was then continued for the
remainder of the experiment.
Radiochemistry
[
11C]Flumazenil was synthesized as previously described
[12] and 3-10 GBq was formulated in 10 mL of saline
containing 7.1 mM NaH2PO4 and 10% v/v ethanol. The
specific activity was 178 ± 69 GBq·μmol
-1 (mean ± stan-
dard deviation (SD)). The radiochemical purity was
higher than 99% as assessed by analytical high perfor-
mance liquid chromatography (HPLC) equipped with
radio and ultraviolet detectors. The HPLC analysis did
not detect any chemical impurities. The identity of [
11C]
flumazenil was confirmed by comparison of the reten-
tion times with the authentic isotopically unmodified
(unlabelled) flumazenil.
PET scanning
Animals were positioned in pairs in a double lutetium
oxyorthosilicate/Lu1.8Y0.2SiO5(Ce) or LSO-LYSO layer
high resolution research tomograph (Siemens/CTI,
Knoxville, TN, USA) PET scanner [13]. First, a trans-
mission scan was acquired using a 740 MBq 2-dimen-
sional fan-collimated
137Cs (662 keV) moving point
source [14]. Next, a dynamic emission scan was
acquired immediately following administration of 7.2 ±
3.3 (mean ± SD) MBq [
11 C]flumazenil to each mouse
or 24.4 ± 6.7 MBq [
11 C]flumazenil to each rat. The
injected activity for each of the different animal groups
and scans is shown in Table 1. Emission data were
acquired for 30 min in 3-dimensional (3D) list mode
and rebinned into the following frame sequences: 4 ×
30, 3 × 60, 2 × 150, and 4 × 300 s (mice) or 6 × 10, 2
×30, 3 × 60, 2 × 150, 2 × 300 and 1 × 600 s (rats). Fol-
lowing corrections for decay, dead time, attenuation,
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3D ordinary Poisson ordered subsets expectation maxi-
mization algorithm for mice and a 3D ordered subsets
weighted least squares algorithm for rats, which show
comparable quantitative accuracy [14]. This resulted in
images with an average spatial resolution of 3 mm full
width at half maximum [13].
Each animal underwent two consecutive [
11C]flumaze-
nil PET scans separated by 100 min to allow for radio-
active decay of carbon-11, with the exception of three
Mdr1a/1b d K Om i c ea n dt h r e eW Tm i c ew h or e c e i v e d
o n l yab a s e l i n e[
11C]flumazenil scan. Tariquidar, 15
mg·kg
-1 , a dose that completely blocks P-gp function,
was administered as a 15-min infusion 35 min before
the second scan to all mice and as a 10-min infusion 20
min before the second scan to all rats, providing optimal
inhibition conditions of tariquidar [9]. Mdr1a/1b dKO
mice received tariquidar to ensure that tariquidar does
not influence [
11 C]flumazenil brain distribution in the
absence of functional P-gp and exclude any P-gp-unre-
lated pharmacokinetic interaction.
In rats the specific activity of [
11C]flumazenil was
modified to study brain distribution of [
11C]flumazenil
at different GABAA receptor occupancies; this was done
by adding four different doses, 5, 20, 100 or 400 μg, of
isotopically unmodified flumazenil to the injection solu-
tions of [
11C]flumazenil (which after synthesis contained
less than 500 ng isotopically unmodified flumazenil).
These doses were chosen based on previous studies of
receptor occupancy by flumazenil in rats [15]. The exact
doses of [
11C]flumazenil and unmodified flumazenil
were calculated based on the specific activity of the tra-
cer solution and the flumazenil concentration in the
solution containing the isotopically unmodified flumaze-
nil and are shown in Table 1. Each rat was assigned to
one flumazenil dose, i.e., both scans obtained in one rat
were performed with the same amount of unlabeled flu-
mazenil. This enabled each rat to act as its own control
when treated with tariquidar.
Flumazenil analysis in rat blood samples
Eight arterial blood samples of 0.1 mL were taken dur-
ing each scan. Blood samples were diluted immediately
using 0.5 mL of 0.42% NaF in water at 0°C to inhibit
esterase activity and thus prevent flumazenil metabolism
in the samples. All samples were stored at -80°C until
analysis.
Flumazenil concentrations in blood were measured
using a method published previously, based on HPLC
coupled to tandem mass spectrometry (LC-MS/MS)
[16]. This analysis was performed in the same labora-
tory and with the same equipment, i.e., under identi-
cal conditions, as described in the study by Liefaard et
al [16]. The limit of detection was 0.5 ng·mL
-1 . Linear
calibration curves were obtained in the range 0.5-
1,000 ng·mL
-1 .
Data analysis
PET image data were analyzed using the freely available
software package Amide 0.9.2 [17]. Time-activity curves
of brain tissue were obtained by drawing a volume of
interest (VOI) in three to four adjacent transaxial planes
to cover the whole brain of mice. In rats, VOIs were
drawn in four adjacent transaxial planes over frontal
cortex, a region in the rat brain with high density of
GABAA receptors. VOI positioning was defined visually
Table 1 Number of mice/rats, together with average (± standard deviation) weight, dose of flumazenil and
radioactivity administered
Mice Rats
Mdr1a/1b WT FMZ FMZ FMZ FMZ
dKO dose 4 μg dose 20 dose 100 dose 400
μg μg μg
Number (n)
Scan 1 10 9 3 3 2 2
Scan 2 6 6 3 3 2 2
Animal weight (g) 31 ± 2 26 ± 2 283 ± 24 267 ± 11 260, 293 265, 270
Radioactivity
[
11C]FMZ (MBq)
Scan 1 7.3 ± 3.0 6.5 ± 2.0 31 ± 8 24 ± 9 30, 34 18, 20
Scan 2 7.0 ± 1.5 7.8 ± 2.0 21 ± 5 18 ± 2 16, 26 21, 16
Exact FMZ dose
(μg)
Scan 1 td td 3.6 ± 0.1 16.3 ± 0.2 83, 87 366, 424
Scan 2 td td 3.9 ± 0.1 17.9 ± 1.0 85, 89 391, 458
Abbreviations: dKO double knockout, WT wild type, FMZ flumazenil, td tracer dose (< 0.1 μg).
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were projected onto all dynamic frames, resulting in
brain time-activity curves of [
11 C]flumazenil. Time
activity curves were normalized for injected dose and
body weight, generating standardized uptake value
(SUV) curves as a function of time:
SUV =
AverageVOIradioactivity

Bq · mL -1
Injected dose

Bq

per bodyweight

g

For comparison of results, the average SUV over the
period from 20-30 min post injection was used. This
average is denoted as SUVbrain and represents the value
at pseudoequilibrium between brain and plasma
concentrations.
In mice SUVbrain was compared between Mdr1a/1b
dKO and WT mice to assess whether [
11C]flumazenil is
a P-gp substrate (genetic disruption model). Further-
more, as a measure of the effect of tariquidar on brain
uptake of [
11C]flumazenil, SUVbrain was compared in all
animals between pre and post tariquidar scans (pharma-
cological inhibition model). The Mdr1a/1b dKO mice
served as controls, as they are devoid of P-gp, which is
the target of tariquidar. For rats, SUVbrain was compared
for each flumazenil dose group separately to investigate
whether P-gp inhibition is affected by receptor occu-
pancy. In addition, in rats, plasma concentrations of flu-
mazenil were compared before and after tariquidar
treatment to determine whether tariquidar had an effect
on plasma kinetics of flumazenil.
Statistical analyses
All statistical analyses were performed in SPSS (version
15.0, IBM Corporation, Armonk, USA). The comparison
of SUVbrain between Mdr1a/1b dKO and WT mice was
carried out by means of independent samples t tests
with Bonferroni correction to adjust for multiple com-
parisons. SUVbrain comparisons before and after P-gp
inhibition for each animal group separately (i.e., rats,
Mdr1a/1b dKO, or WT mice) were performed using
paired samples t tests, again with Bonferroni correction
to adjust for multiple comparisons.
Results and discussion
Ten Mdr1a/1b dKO mice and nine WT mice had suc-
cessful baseline [
11C]flumazenil scans. Of all animals, six
Mdr1a/1b dKO mice, six WT mice and ten rats had
two successful [
11C]flumazenil scans. One WT mouse
died during surgery, and oneMdr1a/1b dKO mouse and
one rat died after tariquidar treatment. The baseline
scan of the mouse that died during the second scan has
been included in the comparison of Mdr1a/1b dKO and
WT mice before P-gp blockade, as this animal appeared
to be healthy before tariquidar treatment. Clearly, for
the comparison before and after tariquidar treatment,
both animals that died during the second scan had to be
excluded. Table 1 shows the animal characteristics,
amount of flumazenil and the activity of [
11C]flumazenil
injected.
Mice
Before treatment with tariquidar, Mdr1a/1b dKO mice
showed higher brain uptake than WT mice throughout
the entire PET scan (Figure 1). The SUVbrain of Mdr1a/
1b dKO mice was 71% higher than the SUVbrain of WT
mice (dKO mice n = 10, SUVbrain = 2.72 ± 0.27 and
WT mice n =9 ,S U V brain = 1.59 ± 0.26; p < 0.001). Fig-
ure 2 shows SUVbrain images of one Mdr1a/1b dKO and
one WT mouse, both before tariquidar administration.
After P-gp blockade, SUVbrain increased by 79% in WT
mice (n = 6, before tariquidar SUVbrain = 1.48 ± 0.14
and after tariquidar SUVbrain = 2.66 ± 0.17; p < 0.001),
while no significant changes were observed in Mdr1a/1b
dKO mice (n=6, before tariquidar SUVbrain =2 . 5 6±
0.20, and after tariquidar SUVbrain = 2.54 ± 0.11; p =
0.8). Furthermore, after tariquidar treatment, the SUV-
brain was not significantly different between WT and
Mdr1a/1b dKO mice (Figure 1; p = 0.2).
Rats
As expected for a receptor ligand, increasing the dose of
unlabeled flumazenil resulted in reduced cerebral uptake
of [
11C]flumazenil (Figure 3). SUVbrain for the group of
rats that received 4 μg flumazenil was similar to that of
WT mice. The more flumazenil added to the tracer
solution, the fewer GABA receptors will be available for
binding; as a consequence, the elimination from brain
was faster. Treatment with 15 mg·kg
-1 tariquidar
increased SUVbrain by 62% (n = 10; before P-gp inhibi-
tion, SUVbrain = 0.49 ± 0.30 and after P-gp inhibition,
SUVbrain = 0.79 ± 0.47; p = 0.001). This increase in
SUVbrain caused by tariquidar treatment was similar for
all flumazenil doses used; 62%, 55%, 59% and 87% for
the 4, 20, 100 and 400 μg dose, respectively. Flumazenil
concentrations in rat plasma, before and after tariquidar
t r e a t m e n t ,a r es h o w ni nF i g u r e4 :t h e r ew e r eo n l ys m a l l
differences between pre and post tariquidar curves
toward the end of the scan.
Taken together, absence of P-gp in mice (genetic dis-
ruption model) had a similar effect on cerebral [
11C]flu-
mazenil uptake as inhibition of P-gp (pharmacological
inhibition model) in WT mice and rats, showing an
approximately 70% higher SUVbrain both in Mdr1a/1b
dKO mice and in P-gp inhibited WT rodents compared
with WT animals prior to P-gp inhibition. Furthermore,
SUVbrain in Mdr1a/1b dKO mice did not change follow-
ing pharmacological P-gp inhibition. Together, these
results demonstrate that [
11 C]flumazenil is a P-gp
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11C]flumazenil does
not appear to be a Bcrp1 substrate in rodents, as SUV-
brain in Mdr1a/1b dKO mice did not change after tari-
quidar treatment compared to baseline.
Theoretically, it is possible that any increase in cerebral
[
11C]flumazenil concentration was due to an increased
plasma [
11C]flumazenil concentration after tariquidar
treatment. To rule out this possibility, plasma flumazenil
concentration curves were compared in rats. There was a
trend for slightly increased plasma concentrations of
flumazenil after tariquidar treatment (Figure 4). The area
under the curve in plasma was increased about 30% for
the 4, 20 and 100 μg flumazenil doses and 5% for the 400
μg flumazenil dose. The increase in plasma concentra-
tions of flumazenil should actually reduce the tariquidar-
caused increase in brain SUV as more isotopically unmo-
dified flumazenil will result in less available receptors for
the tracer to bind to and therefore lead a lower SUV.
Thus, changes in plasma levels of flumazenil could not
account for the observed increase in SUV in the brain
Figure 1 Average cerebral [
11C]flumazenil SUV in mice as function of time. Average cerebral [
11C]flumazenil SUV in wild type (closed
symbols) and Mdr1a/1b double knockout (open symbols) mice before (A) and after (B) i.v. tariquidar administration. Error bars represent SD.
Figure 2 SUVbrain images in mice. Baseline [
11C]flumazenil SUVbrain images (20-30 min post injection) for an Mdr1a/1b dKO (A-C) and a WT (D-
F) mouse. From left to right: transversal, sagittal and coronal slices.
Froklage et al. EJNMMI Research 2012, 2:12
http://www.ejnmmires.com/content/2/1/12
Page 5 of 8but rather reduced the difference between the pre and
post tariquidar scans. The somewhat increased plasma
concentrations of flumazenil during the second scan was
probably a consequence of increased flumazenil distribu-
tion to tissues, e.g., the brain, otherwise protected by P-
gp, which acted as “depot” compartments from which
flumazenil at later time points was redistributed into the
plasma. Furthermore, the fact that SUVbrain in Mdr1a/1b
dKO mice did not change after pharmacological P-gp
inhibition strongly suggests that increased plasma con-
centration of [
11C]flumazenil (if any) did not play a sig-
nificant role. Also, previous test-retest [
11C]flumazenil
studies show no influence of the first scan on the second
scan [15].
Figure 3 Average cerebral [
11C]flumazenil SUV in rats as function of time. Circles, triangles, squares and diamonds indicate the different dose
levels of (unlabeled) flumazenil administered, e.g., 4 (circle), 20 (triangle), 100 (square), and 400 μg( diamond). Open and closed symbols indicate
data before and after tariquidar treatment, respectively. Error bars represent SD.
Figure 4 Average flumazenil plasma concentrations in rats. Circles, triangles, squares and diamonds indicate different dose levels of
flumazenil administered, i.e., 4, 20, 100 and 400 μg, respectively. Open and closed symbols indicate data before and after tariquidar treatment,
respectively.
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gested that flumazenil is not transported by human P-gp
[18,19]. In vitro assays might be less sensitive, as several
transport assays, such as bidirectional transport and cal-
cein inhibition assays have failed to identify moderate P-
gp substrates when these drugs were highly permeable
[18]. In line with the findings of this study, an ex vivo
study [2], described higher [
11C]flumazenil brain-to-
plasma concentration ratios in mice treated with cyclos-
porine A than in control animals. Cyclosporine A, how-
ever, is a first generation P-gp inhibitor, which tends to
be less potent and nonselective than tariquidar and may
also influence metabolism and elimination of drugs/radi-
oligands via interaction with cytochrome P450 enzymes
[20]. Thus, the use of tariquidar is to be preferred over
cyclosporine A to adequately study the influence of P-gp
alteration on brain distribution of drugs/radioligands.
Further, the differences between previous ex vivo rodent
studies and in vitro studies using canine cells (Madin
Darby canine kidney) transfected with human MDR1
gene could be due to species differences in BBB trans-
port of [
11C]flumazenil, which has been observed for
other PET radioligands [21]. Although this study
showed that higher concentrations of P-gp substrates
were found in humans and monkeys compared to
rodents, all radioligands that were P-gp substrates in
rodents were also in humans as well [21]. In the present
in vivo study both genetic disruption and pharmacologi-
cal inhibition of P-gp were used, both providing clear
evidence that cerebral uptake of [
11C]flumazenil can be
affected significantly by P-gp activity.
It should be noted that more avid P-gp substrates,
such as [
11C]verapamil, show a much larger (e.g.
1,000%) increase in brain concentrations after the same
dose of tariquidar [9,10]. Nevertheless, the main finding
of the present study remains valid in that changes in P-
gp function could potentially confound interpretation of
[
11C]flumazenil scans, particularly if there are regional
differences in P-gp upregulation as indicated by some
studies in people with epilepsy [22-24]. Taking the pre-
sent findings into account, focally decreased [
11C]fluma-
zenil uptake may not only be due to decreased GABA-
ergic function, but may also be the result of increased
P-gp activity. If both effects occur simultaneously, the
cerebral [
11C]flumazenil uptake could even be decreased
further. Whether this will affect the interpretation of the
data depends on the purpose of the study. If the aim is
to localize the epileptic focus, decreased [
11C]flumazenil
will, in every case, still help to identify the affected brain
region. However, one will not be able to interpret the
underlying mechanism(s). Furthermore, if future thera-
pies will be developed with the specific aim either to
normalize increased P-gp activity or to compensate for
decreased GABA-ergic inhibition, quantitative informa-
tion is needed on P-gp activity or GABA-ergic function,
which cannot be obtained with [
11C]flumazenil PET
scans alone.
PET studies with [
11C]flumazenil in epileptic rats are
needed to clarify whether local changes in cerebral [
11C]
flumazenil uptake in epilepsy are due to decreased GABA-
ergic function, P-gp upregulation, or both. Furthermore, a
comparison between naive and epileptic rats is needed to
assess to which degree P-gp upregulation affects cerebral
uptake of [
11C]flumazenil. Ultimately, [
11C]flumazenil stu-
dies in both pharmacoresistant and pharmacosensitive
patients with epilepsy, as well as in healthy volunteers are
needed to elucidate this important issue.
Conclusions
The present study showed that [
11C]flumazenil is a P-gp
substrate (but most likely not a Bcrp1 substrate) in
rodents. This finding could have implications for preo-
perative evaluation of people with epilepsy as altered
cerebral [
11C]flumazenil uptake may be due to changes
in both GABAA receptor density and P-gp activity,
potentially complicating interpretation of data.
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